Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and ...

The company believes these combinations create a broader approach to treating neurodegenerative diseases ・Preclinical studies have demonstrated these combinations significant ...

The benefits do not stop there. Recent studies suggest GLP-1 drugs may also reduce the risk of heart disease, kidney disease and stroke, and even possibly protect the brain from AD by reducing ...

Nicox, and Glaukos ink exclusive NCX 1728 research and global licensing option agreement: Sophia Antipolis, France Tuesday, September 24, 2024, 17:00 Hrs [IST] Nicox SA, an intern ...

Heart disease is a type of cardiovascular disease that affects the heart’s structure and function. Several different heart ...

The sexual response cycle sets off a spiral of sensory effects in the body. Learn about the phases here and what happens to ...

Thousand Oaks, California Friday, October 4, 2024, 14:00 Hrs [IST] ...

Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

The rise in research and development activities in schizophrenia treatment is driving market growth by fostering the development of innovative therapies, including novel antipsychotics and ...